Search Results
Search for other papers by Elisa Lamback in
Google Scholar
PubMed
Search for other papers by Renan Lyra Miranda in
Google Scholar
PubMed
Search for other papers by Leila Chimelli in
Google Scholar
PubMed
Search for other papers by Felipe Andreiuolo in
Google Scholar
PubMed
Search for other papers by Leandro Kasuki in
Google Scholar
PubMed
Search for other papers by Luiz Eduardo Armondi Wildemberg in
Google Scholar
PubMed
Search for other papers by Monica R Gadelha in
Google Scholar
PubMed
Pituitary gigantism is a rare pediatric disorder caused by excess growth hormone (GH) secretion. In almost 50% of cases, a genetic cause can be identified, with pathogenic variants in the aryl hydrocarbon receptor interacting protein (AIP) gene being the most common. We present a case of a 11-year-old boy who exhibited progressive vision loss, associated with accelerated linear growth and weight gain. On physical examination, he had enlarged hands, right eye amaurosis, and was already above his target height. Increased GH and IGF-I concentrations confirmed the diagnosis of pituitary gigantism. A magnetic resonance imaging showed a giant sellar lesion with supra- and para-sellar extensions. He underwent two surgeries which did not achieve cure or visual improvement. Histopathological analysis revealed a sparsely granulated tumor, negative for somatostatin receptor type 2 (SST2) and immunoreactivity score of 6 for somatostatin receptor type 5 (SST5). Our published artificial intelligence prediction model predicted an 83% chance of not responding to first-generation somatostatin receptor ligands. Pasireotide was therefore prescribed and afterwards cabergoline was added on. IGF-I concentrations decreased, but did not normalize. We discovered a novel germline single nucleotide variant in the splicing donor region of intron 2 of AIP gene (NM_003977.4:c.279+1 G>A), classified as likely pathogenic according to the American College of Medical Genetics and Genomics guidelines.
